The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

DOTG     1,2-bis(2- methylphenyl)guanidine

Synonyms: Nocceler DT, Sanceler DT, Soxinol DT, Vulkacite DOTG, Tocris-0841, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Eveite DOTG

  • In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine [1].
 

High impact information on Eveite DOTG

 

Biological context of Eveite DOTG

 

Anatomical context of Eveite DOTG

 

Associations of Eveite DOTG with other chemical compounds

 

Gene context of Eveite DOTG

  • BD1047 and BD1063 dose-dependently attenuated the dystonia produced by DTG, suggesting a receptor-mediated mechanism, and the dose curve for DTG was shifted to the right in the presence of the novel ligands [11].
  • The sigma ligands, 1,3-di-o-tolylguanidine (DTG) and (-)-deoxy-N-benzylnormetazocine, produced a significant increase both in contralateral turning and in tyrosine hydroxylase activity [16].
  • In radioligand binding experiments on membranes from human atrial appendages (alpha 2- and sigma-binding sites were masked), cannabinoid receptor ligands and IR agonists displaced the radiolabeled guanidine derivative [3H]DTG (1,3-di-o-tolyguanidine, an agonist at presynaptic IRs) from its binding sites [17].
 

Analytical, diagnostic and therapeutic context of Eveite DOTG

  • Microinjection of the high affinity sigma ligands, di-o-tolylguanidine or haloperidol (0-10 nmol/0.5 microl), produced a marked increase in vacuous chewing and facial tremors in rats, while coadministration of the functional sigma antagonists, BD1047 or BD1063 (5 nmol), greatly attenuated these drug-induced movements [18].
  • Pregnant rats were given 1,3-di-o-tolylguanidine (DTG) by gavage at 0, 10, 20 or 40mg/kgbw/day on days 6-19 of pregnancy and the pregnancy outcome was determined on day 20 of pregnancy [19].

References

  1. Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice. Matsumoto, R.R., McCracken, K.A., Friedman, M.J., Pouw, B., De Costa, B.R., Bowen, W.D. Eur. J. Pharmacol. (2001) [Pubmed]
  2. Protein phosphorylation and calcium uptake into rat forebrain synaptosomes: modulation by the sigma ligand, 1,3-ditolylguanidine. Brent, P.J., Herd, L., Saunders, H., Sim, A.T., Dunkley, P.R. J. Neurochem. (1997) [Pubmed]
  3. Synthesis and in vitro evaluation of 5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indoles: high-affinity ligands for the N,N'-di-o-tolylguanidine-labeled sigma binding site. Mewshaw, R.E., Sherrill, R.G., Mathew, R.M., Kaiser, C., Bailey, M.A., Karbon, E.W. J. Med. Chem. (1993) [Pubmed]
  4. Interaction of sigma-compounds with receptor-stimulated phosphoinositide metabolism in the rat brain. Candura, S.M., Coccini, T., Manzo, L., Costa, L.G. J. Neurochem. (1990) [Pubmed]
  5. Synthesis and structure-activity relationships of N,N'-di-o-tolylguanidine analogues, high-affinity ligands for the haloperidol-sensitive sigma receptor. Scherz, M.W., Fialeix, M., Fischer, J.B., Reddy, N.L., Server, A.C., Sonders, M.S., Tester, B.C., Weber, E., Wong, S.T., Keana, J.F. J. Med. Chem. (1990) [Pubmed]
  6. Effects of subcutaneous and intracerebroventricular administration of the sigma receptor ligand 1,3-Di-o-tolylguanidine on body temperature in the rat: interactions with BMY 14802 and rimcazole. Bejanian, M., Pechnick, R.N., Bova, M.P., George, R. J. Pharmacol. Exp. Ther. (1991) [Pubmed]
  7. Sigma receptor ligands modulate contractility, Ca++ influx and beating rate in cultured cardiac myocytes. Ela, C., Barg, J., Vogel, Z., Hasin, Y., Eilam, Y. J. Pharmacol. Exp. Ther. (1994) [Pubmed]
  8. p-chlorophenylalanine-reversible reduction of sigma binding sites by chronic imipramine treatment in rat brain. Shirayama, Y., Nishikawa, T., Umino, A., Takahashi, K. Eur. J. Pharmacol. (1993) [Pubmed]
  9. RU 3117 a steroidal compound with high affinity for sigma sites in rat testis membranes. Bonfils, A., Humbert, J., Philibert, D. J. Steroid Biochem. Mol. Biol. (1996) [Pubmed]
  10. The sigma ligand 1,3-di-o-tolylguanidine depresses amino acid-induced excitation non-selectively in rat brain. Connick, J.H., Addae, J.I., Nicholson, C.D., Stone, T.W. Eur. J. Pharmacol. (1992) [Pubmed]
  11. Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism. Matsumoto, R.R., Bowen, W.D., Tom, M.A., Vo, V.N., Truong, D.D., De Costa, B.R. Eur. J. Pharmacol. (1995) [Pubmed]
  12. Radiosynthesis, cerebral distribution, and binding of [125I]-1-(p-iodophenyl)-3-(1-adamantyl)guanidine, a ligand for sigma binding sites. Kimes, A.S., Wilson, A.A., Scheffel, U., Campbell, B.G., London, E.D. J. Med. Chem. (1992) [Pubmed]
  13. Differential effects of repeated dl-pentazocine treatment on sigma binding sites in discrete brain areas of the rat. Shirayama, Y., Nishikawa, T., Takahashi, K. Neurosci. Lett. (1994) [Pubmed]
  14. Phosphorylation of synapsin I and dynamin in rat forebrain synaptosomes: modulation by sigma (sigma) ligands. Brent, P.J., Haynes, H., Jarvie, P.E., Mudge, L., Sim, A.T., Dunkley, P.R. Neurosci. Lett. (1995) [Pubmed]
  15. Evidence that the NH2-terminus of substance P modulates N-methyl-D-aspartate-induced activity by an action involving sigma receptors. Hornfeldt, C.S., Kitto, K.F., Larson, A.A. Eur. J. Pharmacol. (1996) [Pubmed]
  16. Stimulation of rat striatal tyrosine hydroxylase activity following intranigral administration of sigma receptor ligands. Weiser, S.D., Patrick, S.L., Mascarella, S.W., Downing-Park, J., Bai, X., Carroll, F.I., Walker, J.M., Patrick, R.L. Eur. J. Pharmacol. (1995) [Pubmed]
  17. Presynaptic imidazoline receptors. New developments in characterization and classification. Göthert, M., Brüss, M., Bönisch, H., Molderings, G.J. Ann. N. Y. Acad. Sci. (1999) [Pubmed]
  18. Microinjection of sigma ligands into cranial nerve nuclei produces vacuous chewing in rats. Tran, T.T., de Costa, B.R., Matsumoto, R.R. Psychopharmacology (Berl.) (1998) [Pubmed]
  19. Prenatal developmental toxicity study of the basic rubber accelerator, 1,3-di-o-tolylguanidine, in rats. Ema, M., Fujii, S., Matsumoto, M., Hirose, A., Kamata, E. Reprod. Toxicol. (2006) [Pubmed]
 
WikiGenes - Universities